Market Overview

UPDATE: Bank of America Reinstates Coverage on Incyte on Two Oncology Platforms


In a report published Wednesday, Bank of America analyst Steve Byrne reinstated coverage on Incyte (NASDAQ: INCY) with a Buy rating and $84.00 price target.

In the report, Bank of America noted, “We are reinstating coverage of Incyte (INCY) with a Buy rating and $84 PO. The company's single commercial product Jakafi (ruxolitinib, oral blocker of JAK1/JAK2) accounts for half of our valuation, driven by double digit revenue growth that could accelerate in early 2015 with approval in a new indication. The balance of our PO is from INCY's pipeline, largely driven by the significant long-term potential of the company's IDO inhibitor and pipeline of JAK inhibitors as broad oncology platforms as both interrupt tumor cells' ability to evade the immune system (via T-cell inhibition and tumor-induced inflammation, respectively). While still early in development, the potential to serve as combo backbone drugs is compelling.”

Incyte closed on Tuesday at $68.37.

Latest Ratings for INCY

Nov 2020Morgan StanleyMaintainsEqual-Weight
Nov 2020BMO CapitalMaintainsMarket Perform
Oct 2020B of A SecuritiesMaintainsBuy

View More Analyst Ratings for INCY
View the Latest Analyst Ratings


Related Articles (INCY)

View Comments and Join the Discussion!

Posted-In: Bank of America Steve ByrneAnalyst Color Initiation Analyst Ratings

Latest Ratings

HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at